Q-omics provides the consensus-scored CRIM1-DT profile across patient tissues and cancer cell-line models. CRIM1-DT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CRIM1-DT is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CRIM1-DT RNA expression shows 14,226 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, COAD, and THYM as cancer lineages where CRIM1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRIM1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRIM1-DT survival associations across molecular data types. CRIM1-DT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRIM1-DT RNA expression–survival associations across cancer types. High CRIM1-DT expression shows unfavorable associations in LUAD, UCEC and HNSC, but favorable associations in UCS, THCA and LUSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CRIM1-DT RNA expression.
This table summarizes CRIM1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CRIM1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRIM1-DT shows lower tumor expression in COAD, LUAD, THCA, KICH and READ and higher tumor expression in LIHC. The COAD box plot shows higher CRIM1-DT RNA expression in normal versus tumor tissue (log2 FC = −1.874, t-test p < 0.001).
This table shows molecular features associated with CRIM1-DT in patient tissues and cancer cell lines. In patient samples, CRIM1-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
